Oversold Stocks: Travere, Hims, and Enovis Present Buying Opportunities
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Should l Buy ENOV?
Source: Benzinga
- Travere Drug Review Extended: The FDA has extended the review timeline for Travere Therapeutics' Filspari sNDA to April 13, causing the stock to drop approximately 23% over the past month, with an RSI of 29.7 indicating oversold conditions that may present a buying opportunity for investors.
- Hims Stock Coverage Initiated: Evercore ISI analyst initiated coverage on Hims & Hers Health with an In-Line rating and a price target of $33, despite the stock falling around 13% in the last month, with an RSI of 29.7 suggesting undervaluation that could attract investor interest.
- Enovis Buy Rating Issued: BTIG analyst assigned a Buy rating to Enovis Corp with a price target of $41, even as the stock declined about 14% in the past five days, with an RSI of 29.6 indicating oversold conditions that may offer potential rebound opportunities for investors.
- Market Trend Analysis: Benzinga Pro's charting tools indicate that trends in Hims and Enovis stocks are forming, allowing investors to leverage these oversold signals for strategic positioning and capitalize on potential market rebounds.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ENOV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ENOV
Wall Street analysts forecast ENOV stock price to rise
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 21.910
Low
40.00
Averages
45.25
High
50.00
Current: 21.910
Low
40.00
Averages
45.25
High
50.00
About ENOV
Enovis Corporation is a medical technology company. It is focused on developing clinically differentiated solutions by manufacturing and distributing high-quality medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. It operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative diseases. The Prevention & Recovery products are marketed under several brand names, such as DJO. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. It also operates a Enovis Growth eXcellence business system (EGX).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Enovis Corporation Rated 'Outperform' by Evercore ISI Despite Weak Stock Performance
- Weak Stock Performance: Enovis Corporation faced a challenging year in 2025, with its stock down 50% and hitting a 52-week low of $21.00 on January 29, 2026, indicating significant macroeconomic pressures affecting its performance.
- Analyst Rating Reaffirmed: Evercore ISI analyst Vijay Kumar reiterated an 'Outperform' rating on January 12, setting a $40 price target, acknowledging a revenue miss of about 3% below expectations but projecting an EPS beat due to higher-margin reconstructive operations.
- Optimistic Cash Flow Outlook: Evercore ISI forecasts improved cash flow for FY26, with free cash flow conversion expected to exceed 25% in Q4, suggesting a potential for stronger financial performance in the near future.
- Diversified Strategy Support: BTIG analyst Ryan Zimmerman initiated coverage on Enovis on January 6, 2026, with a 'Buy' rating and a $41 price target, reflecting confidence in the company's multi-segment orthopedic strategy despite concerns regarding scale, tariffs, and cash flow.
See More
Oversold Stocks: Travere, Hims, and Enovis Present Buying Opportunities
- Travere Drug Review Extended: The FDA has extended the review timeline for Travere Therapeutics' Filspari sNDA to April 13, causing the stock to drop approximately 23% over the past month, with an RSI of 29.7 indicating oversold conditions that may present a buying opportunity for investors.
- Hims Stock Coverage Initiated: Evercore ISI analyst initiated coverage on Hims & Hers Health with an In-Line rating and a price target of $33, despite the stock falling around 13% in the last month, with an RSI of 29.7 suggesting undervaluation that could attract investor interest.
- Enovis Buy Rating Issued: BTIG analyst assigned a Buy rating to Enovis Corp with a price target of $41, even as the stock declined about 14% in the past five days, with an RSI of 29.6 indicating oversold conditions that may offer potential rebound opportunities for investors.
- Market Trend Analysis: Benzinga Pro's charting tools indicate that trends in Hims and Enovis stocks are forming, allowing investors to leverage these oversold signals for strategic positioning and capitalize on potential market rebounds.
See More
Analysts Adjust Ratings on Wealthfront and Spire Global with Price Targets
- Wealthfront Rating Initiation: Keybanc analyst Alex Markgraff initiated coverage on Wealthfront Corp (NASDAQ:WLTH) with a Sector Weight rating, reflecting a cautious market sentiment as shares closed at $13.65.
- Spire Global Buy Rating: HC Wainwright & Co. analyst Scott Buck initiated coverage on Spire Global Inc (NYSE:SPIR) with a Buy rating and a price target of $14, indicating strong confidence in its growth potential as shares closed at $8.21.
- Enovis Rating Upgrade: BTIG analyst Ryan Zimmerman initiated coverage on Enovis Corp (NYSE:ENOV) with a Buy rating and a price target of $41, suggesting optimistic market expectations as shares closed at $27.01.
- Evommune Rating Initiation: HC Wainwright & Co. analyst Mitchell S. Kapoor initiated coverage on Evommune Inc (NYSE:EVMN) with a Buy rating and a price target of $35, reflecting a positive outlook as shares closed at $15.37.
See More
Enovis Appoints Oliver Engert as Chief Administrative Officer to Drive Strategic Development
- Strategic Leadership Appointment: Enovis has appointed Oliver Engert as Chief Administrative Officer, responsible for driving the company's strategy development and organizational efficiency, aimed at supporting the next phase of profitable and capital-efficient growth.
- Rich Experience Background: Oliver brings 30 years of experience from McKinsey & Company, where he served as Senior Partner, focusing on strategy, transformations, and performance improvement, which is expected to provide valuable external insights and expertise to Enovis.
- Executive Team Enhancement: CEO Damien McDonald highlighted that Oliver's appointment comes at a critical time for Enovis, emphasizing its importance in driving growth and improving efficiency to better meet patient needs.
- Educational Background Advantage: Oliver holds a bachelor's degree in economics from the Wharton School of the University of Pennsylvania and an MBA from the Amos Tuck School of Business at Dartmouth College, further enhancing his leadership capabilities in the medical technology sector.
See More
Enovis (ENOV) Insider Makes Significant Investment by Acquiring 2,468 Shares
Insider Purchase: John Kleckner, the Principal Accounting Officer of Enovis Corporation, purchased 2,468 shares on November 25, 2025, indicating confidence in the company's stock recovery after a significant downturn.
Company Performance: Enovis Corporation has faced a 38.6% decline in share price over the past year, largely due to expanding net losses, including a substantial non-cash goodwill impairment charge in the third quarter.
Sales Growth: Despite the overall financial struggles, the company reported year-over-year sales growth in its Recon and P&R segments, with increases of 12% and 6%, respectively, in the third quarter.
Market Context: The article highlights the importance of insider trading as a potential indicator of future stock performance, suggesting that Kleckner's purchase reflects a belief in the company's potential for recovery.
See More
Wells Fargo Keeps Overweight Rating on Enovis and Increases Price Target to $42
Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform is designed to help traders succeed in the markets with accurate stock market intelligence.
See More
Enovis Corporation Rated 'Outperform' by Evercore ISI Despite Weak Stock Performance
- Weak Stock Performance: Enovis Corporation faced a challenging year in 2025, with its stock down 50% and hitting a 52-week low of $21.00 on January 29, 2026, indicating significant macroeconomic pressures affecting its performance.
- Analyst Rating Reaffirmed: Evercore ISI analyst Vijay Kumar reiterated an 'Outperform' rating on January 12, setting a $40 price target, acknowledging a revenue miss of about 3% below expectations but projecting an EPS beat due to higher-margin reconstructive operations.
- Optimistic Cash Flow Outlook: Evercore ISI forecasts improved cash flow for FY26, with free cash flow conversion expected to exceed 25% in Q4, suggesting a potential for stronger financial performance in the near future.
- Diversified Strategy Support: BTIG analyst Ryan Zimmerman initiated coverage on Enovis on January 6, 2026, with a 'Buy' rating and a $41 price target, reflecting confidence in the company's multi-segment orthopedic strategy despite concerns regarding scale, tariffs, and cash flow.
See More
Oversold Stocks: Travere, Hims, and Enovis Present Buying Opportunities
- Travere Drug Review Extended: The FDA has extended the review timeline for Travere Therapeutics' Filspari sNDA to April 13, causing the stock to drop approximately 23% over the past month, with an RSI of 29.7 indicating oversold conditions that may present a buying opportunity for investors.
- Hims Stock Coverage Initiated: Evercore ISI analyst initiated coverage on Hims & Hers Health with an In-Line rating and a price target of $33, despite the stock falling around 13% in the last month, with an RSI of 29.7 suggesting undervaluation that could attract investor interest.
- Enovis Buy Rating Issued: BTIG analyst assigned a Buy rating to Enovis Corp with a price target of $41, even as the stock declined about 14% in the past five days, with an RSI of 29.6 indicating oversold conditions that may offer potential rebound opportunities for investors.
- Market Trend Analysis: Benzinga Pro's charting tools indicate that trends in Hims and Enovis stocks are forming, allowing investors to leverage these oversold signals for strategic positioning and capitalize on potential market rebounds.
See More
Analysts Adjust Ratings on Wealthfront and Spire Global with Price Targets
- Wealthfront Rating Initiation: Keybanc analyst Alex Markgraff initiated coverage on Wealthfront Corp (NASDAQ:WLTH) with a Sector Weight rating, reflecting a cautious market sentiment as shares closed at $13.65.
- Spire Global Buy Rating: HC Wainwright & Co. analyst Scott Buck initiated coverage on Spire Global Inc (NYSE:SPIR) with a Buy rating and a price target of $14, indicating strong confidence in its growth potential as shares closed at $8.21.
- Enovis Rating Upgrade: BTIG analyst Ryan Zimmerman initiated coverage on Enovis Corp (NYSE:ENOV) with a Buy rating and a price target of $41, suggesting optimistic market expectations as shares closed at $27.01.
- Evommune Rating Initiation: HC Wainwright & Co. analyst Mitchell S. Kapoor initiated coverage on Evommune Inc (NYSE:EVMN) with a Buy rating and a price target of $35, reflecting a positive outlook as shares closed at $15.37.
See More
Enovis Appoints Oliver Engert as Chief Administrative Officer to Drive Strategic Development
- Strategic Leadership Appointment: Enovis has appointed Oliver Engert as Chief Administrative Officer, responsible for driving the company's strategy development and organizational efficiency, aimed at supporting the next phase of profitable and capital-efficient growth.
- Rich Experience Background: Oliver brings 30 years of experience from McKinsey & Company, where he served as Senior Partner, focusing on strategy, transformations, and performance improvement, which is expected to provide valuable external insights and expertise to Enovis.
- Executive Team Enhancement: CEO Damien McDonald highlighted that Oliver's appointment comes at a critical time for Enovis, emphasizing its importance in driving growth and improving efficiency to better meet patient needs.
- Educational Background Advantage: Oliver holds a bachelor's degree in economics from the Wharton School of the University of Pennsylvania and an MBA from the Amos Tuck School of Business at Dartmouth College, further enhancing his leadership capabilities in the medical technology sector.
See More
Enovis (ENOV) Insider Makes Significant Investment by Acquiring 2,468 Shares
Insider Purchase: John Kleckner, the Principal Accounting Officer of Enovis Corporation, purchased 2,468 shares on November 25, 2025, indicating confidence in the company's stock recovery after a significant downturn.
Company Performance: Enovis Corporation has faced a 38.6% decline in share price over the past year, largely due to expanding net losses, including a substantial non-cash goodwill impairment charge in the third quarter.
Sales Growth: Despite the overall financial struggles, the company reported year-over-year sales growth in its Recon and P&R segments, with increases of 12% and 6%, respectively, in the third quarter.
Market Context: The article highlights the importance of insider trading as a potential indicator of future stock performance, suggesting that Kleckner's purchase reflects a belief in the company's potential for recovery.
See More
Wells Fargo Keeps Overweight Rating on Enovis and Increases Price Target to $42
Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform is designed to help traders succeed in the markets with accurate stock market intelligence.
See More
